At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Amicus Therapeutics is a biopharmaceutical company developing next-generation treatments for a broad range of human genetic diseases, with a focus on improving therapies for lysosomal storage diseases.
More...
NEWS
08/20/2014 Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
08/07/2014 Amicus Therapeutics Announces Second Quarter 2014 Financial Results and Corporate Updates
07/31/2014 Amicus Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014
More...

U.S. NEWS
Agonizing Choices for Lives Saved by Miracle Drugs
By GEETA ANAND

Seven months ago, Megan Crowley made a gutsy decision: to undergo a radical surgery to  straighten out her spine, which has been crippled by Pompe disease. Photo: Lexey Swall
Click Here to Read the Article
Click Here to View the Video

Copyright © 2013 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy